Newsroom Archives - Spectral Medical Inc

Spectral Medical Provides Update on PMA Submission Timing for PMX-20R

TORONTO, Canada – February 26, 2026 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval...

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update

PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Canada – Nov. 07, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...

Spectral Medical Announces Publication of EDEN Observational Study

New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Canada – September 16, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic...

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025

Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Canada – September 8, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic...

Spectral Medical Receives US$3 Million From Vantive

TORONTO, Canada – August 25, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B...

Spectral Medical and Vantive Announce Topline Results from Spectral’s TIGRIS Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock

Results exceed prespecified primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality. Pooled absolute risk reduction of 8.3%; Relative risk reduction of 18% Key secondary endpoint: 90-day Mortality 17.4% lower with PMX and >99%...

« Older Entries

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.